Treatment A (BGF MDI HFO with oral activated charcoal) for Chronic Obstructive Pulmonary Disease

"We have evaluated Treatment A (BGF MDI HFO with oral activated charcoal) and judged its safety to be a 1, indicating that there is limited data available which supports the efficacy of this treatment."

"This clinical trial has set the criteria for enrolment to include any adults aged 18-60 who suffer from chronic obstructive airway disease. A total of 108 participants are necessary in order to complete this medical research."

"Affirmative. Clinicaltrials.gov data highlights that this clinical trial is currently looking for individuals to participate, which was originally launched on July 29th 2022 and has seen its last update on October 6th 2022. A total of 108 patients are requested from one medical site."

"The primary endpoint, which will be assessed over a 48-hour period of each treatment cycle, is Area Under the Curve from time zero to infinity (AUCinf). Moreover, AstraZeneca's clinical trial also plans on evaluating secondary outcomes such as Percentage of subjects with clinically relevant changes in pulse rate; Percentage of subjects with noteworthy alterations in 12-lead ECGs; and Half life related to terminal slope (λz) on semi logarithmic concentration curves (t½λz), all pertaining to BGF MDI HFO/BGF MDI HFA combined with oral activated charcoal."

"To be considered for this trial, participants must range in age from 18 to 60. In contrast, there are 14 trials designed specifically for those under the legal age and 333 studies open to seniors above 65 years old."

"This medical trial is still recruiting participants, as evidenced by the data hosted on clinicaltrials.gov. The listing was first published July 29th 2022 and has recently been updated October 6th of that same year."